|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11,988 GBX | -0.32% |
|
+9.52% | +13.09% |
| Apr. 26 | ASTRAZENECA : DZ Bank sticks Neutral | ZD |
| Apr. 26 | ASTRAZENECA : UBS keeps a Sell rating | ZD |
LONDON (Reuters) - Astrazeneca on Thursday said the sale of contract drugmaker Catalent to the parent of Novo Nordisk this week demonstrates the importance of building an independent supply chain.
AstraZeneca is a client of Catalent for some of its drug manufacturing, but AstraZeneca is working to boost its in-house capacity to cut reliance on contract drugmakers, Chief Executive Pascal Soriot told reporters after the release of fourth-quarter results.
(Reporting by Maggie Fick in London and Eva Mathews in Bengaluru; Editing by David Goodman)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 11,988 GBX | -0.32% | +9.52% | 231B | ||
| 886.6 DKK | +2.28% | +2.36% | 566B | ||
| 55.92 USD | +0.22% | +0.79% | 10.12B | ||
| 1st Jan change | Capi. | |
|---|---|---|
| +13.09% | 231B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B | |
| -11.77% | 144B |
ASTRAZENECA PLC 
